ArticleThe Journal of pathology2019
Distinct mutational landscape of inverted urothelial papilloma.
Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 20 citations in OpenAlex.
- Quantitative differentiation of non-invasive bladder urothelial carcinoma and inverted papilloma based on CT urography.BMC urology · 2024Article
- Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.Nature communications · 2023Article
- Distinctive morphological and molecular features of urothelial carcinoma with an inverted growth pattern.Journal of pathology and translational medicine · 2021Review
- Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis.Clinics and practice · 2021Review
- Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities.The Journal of pathology · 2020Article
- A new era in the detection of urothelial carcinoma by sequencing cell-free DNA.Translational andrology and urology · 2019Article
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A recent study has identified gene mutations involving the MAPK/ERK pathway, particularly the HRAS gene, in all inverted urothelial papillomas (IUPs), in the absence of pathway mutations in TERT promoter, FGFR3, and TP53/RB1genes. Neither recurrence nor progression was observed in IUPs. These data support several longstanding hypotheses: (1) IUPs are benign and do not recur or progress; (2) they harbor mutations that are different from those of urothelial carcinoma; and (3) they arise through different molecular mechanisms than low- or high-grade urothelial carcinoma. As the most critical differential diagnosis in this context is inverted-type urothelial carcinoma, more comprehensive studies are needed to compare and contrast these entities. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.